– USA, MA – Beta Bionics, Inc., a clinical-stage medical technology company committed to the design, development, and commercialization of the iLet Bionic Pancreas, today announced the appointment of Gilad Glick to its Board of Directors.
“We are delighted to welcome Gilad to our Board of Directors, and look forward to working with him as we prepare for the commercialization phase of the iLet® Bionic Pancreas,” said Founder and Executive Chair, Dr. Ed Damiano. “His expertise within the healthcare and medical device industry, and his strong strategic, commercial, and international experience will be instrumental to the growth and maturation of our organization and business over the coming years.”
The company also announced the appointment of Dr. Veena Rao (Ph.D.) to the role of Chief Commercial Officer.
Rao was previously Beta Bionics’ VP of Business Development and interim CCO.
About Gilad Glick
Gilad Glick is the former CEO of Itamar Medical and has over 25 years of medical device experience across Europe and the U.S., within a variety of functional areas focused on commercialization, strategy, sales, marketing, and research and development. Prior to joining Itamar Medical as CEO, Glick served as Vice President of Worldwide Sales and Marketing at Biosense Webster, a Johnson & Johnson company, overseeing all strategic and commercial activities.
“I look forward to working with a dedicated and passionate management team committed to improving the lives of people with diabetes,” said Gilad Glick. “It is rewarding to have the opportunity to contribute to Beta Bionics’ public benefit mission, as the team seeks to improve the lives of people unable to reach glycemic goals with currently available diabetes technology and help reduce the cognitive burden experienced by people with type 1 diabetes, as well as their families and physicians.”
Gilad Glick is a member of Israel’s 8400 Heath Network, a founder of the MedTech Commercialization Institute and a member of Almeda Venture MedTech Fund’s Board of Directors.
He earned a Master of Business Administration from the Maastricht School of Management in the Netherlands, majoring in General and Strategic Management. He is also a graduate of the Strategic Marketing Management Executive Program at the Stanford Graduate School of Business.
About Beta Bionics
Beta Bionics is a clinical stage medical technology company focused on the design, development, and commercialization of its iLet Bionic Pancreas in both the insulin dosing (the iLet) and bihormonal (iLet Duo) configurations. The iLet Bionic Pancreas platform is designed to use adaptive, self-learning, control algorithms, together with continuous glucose monitoring and pump technology, to autonomously compute and administer doses of insulin and/or glucagon and mimic the body’s natural ability to maintain tight glycemic control. Beta Bionics is a for-profit, public benefit corporation and Certified B Corporation. Since its founding in 2015, its mission is to help improve health outcomes and the quality of life of children and adults living with diabetes and other conditions of glycemic dysregulation.
For more information : https://www.betabionics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.